Ipsen And Day One Earlier Announced Exclusive Ex U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Ipsen And Day One Earlier Announced Exclusive Ex U.S. Licensing Agreement To Commercialize Tovorafenib For The Most Common Childhood Brain Tumor
Ipsen ((Euronext: IPN, OTC:IPSEY) and Day One Biopharmaceuticals (NASDAQ:DAWN) (Day One), announced today a new global partnership outside the U.S. for tovorafenib, an oral, once-weekly, type II RAF inhibitor for pediatric low grade glioma (pLGG), the most common form of childhood brain cancer, i and any future indications developed by Day One.
今日，艾普生（Euronext: IPN，OTC: IPSEY）和第一天生物製藥公司（NASDAQ: DAWN）（Day One）宣佈，就口服的一週一次的Ⅱ型RAF抑制劑tovorafenib的兒童低級別膠質瘤（pLGG）——是兒童最常見的一種腦癌——以及Day One開發的任何未來適應症，在美國以外的地區建立新的全球合作伙伴關係。
Under the terms of the agreement, Ipsen will be responsible for the regulatory and commercial activities for tovorafenib in all territories outside of the U.S. Day One will receive an upfront payment of approximately $111 million, which includes approximately $71 million in cash as well as a $40 million equity investment at a premium and up to approximately $350 million in additional launch and sales milestone payments. Day One will receive tiered double-digit royalties starting at mid-teens percentage on sales.
根據協議，艾普生將負責美國以外所有地區tovorafenib的監管和商業活動。Day One將獲得大約11100萬美元的首付款項，其中包括大約7100萬美元的現金，以及以溢價形式的4000萬美元股票投資和最多約35000萬美元的額外推出和銷售里程碑款項。Day One將獲得雙位數的銷售提成，從銷售中的中位數百分比開始計算。
譯文內容由第三人軟體翻譯。
